The United Kingdom's stock market has recently experienced a downturn, with the FTSE 100 index closing lower due to weak trade data from China, highlighting concerns about global economic recovery. In such an environment, identifying stocks that might be trading below their estimated value can offer potential opportunities for investors looking to capitalize on undervaluation amid broader market challenges.

Top 10 Undervalued Stocks Based On Cash Flows In The United Kingdom

Name Current Price Fair Value (Est) Discount (Est) Dr. Martens (LSE:DOCS) £0.6105 £1.19 48.6% GlobalData (AIM:DATA) £1.79 £3.37 46.9% Deliveroo (LSE:ROO) £1.257 £2.50 49.6% AstraZeneca (LSE:AZN) £120.28 £219.10 45.1% Duke Capital (AIM:DUKE) £0.3025 £0.55 44.6% Likewise Group (AIM:LIKE) £0.195 £0.37 47.6% Calnex Solutions (AIM:CLX) £0.52 £1.03 49.7% Kromek Group (AIM:KMK) £0.0585 £0.11 48.5% Optima Health (AIM:OPT) £1.82 £3.31 45% Savannah Energy (AIM:SAVE) £0.105 £0.20 48.7%

Click here to see the full list of 57 stocks from our Undervalued UK Stocks Based On Cash Flows screener.

We'll examine a selection from our screener results.

ConvaTec Group

Overview: ConvaTec Group PLC develops, manufactures, and sells medical products, services, and technologies across Europe, North America, and internationally with a market cap of £5.47 billion.

Operations: The company's revenue is primarily generated from the development, manufacture, and sale of medical products and technologies, amounting to $2.29 billion.

Estimated Discount To Fair Value: 36%

ConvaTec Group appears undervalued, trading at £2.67, 36% below its estimated fair value of £4.18. The company's earnings grew by 46.2% last year and are forecast to grow annually at 16.9%, outpacing the UK market's 14.1%. Despite high debt levels, ConvaTec maintains a strong financial position with operating profit growth projected at 12% for 2025 and a net income increase to US$190.5 million from US$130.3 million in the prior year.

Our growth report here indicates ConvaTec Group may be poised for an improving outlook. Take a closer look at ConvaTec Group's balance sheet health here in our report.LSE:CTEC Discounted Cash Flow as at Mar 2025

Genus

Overview: Genus plc is an animal genetics company with operations across North America, Latin America, the United Kingdom, the rest of Europe, the Middle East, Russia, Africa and Asia; it has a market cap of £1.25 billion.

Operations: The company's revenue is derived from two main segments: Genus ABS, which contributes £311.10 million, and Genus PIC, which accounts for £358 million.

Estimated Discount To Fair Value: 19%

Genus plc, trading at £19.04, is undervalued relative to its fair value estimate of £23.5. Despite recent earnings showing a decline in net income to £1.5 million from £10.3 million year-on-year, analysts forecast robust profit growth of 46.67% annually over the next three years, outpacing market averages and expected to achieve profitability within this period. However, the stock exhibits high volatility and a low forecasted return on equity of 12.5%.

Story Continues

In light of our recent growth report, it seems possible that Genus' financial performance will exceed current levels. Delve into the full analysis health report here for a deeper understanding of Genus.LSE:GNS Discounted Cash Flow as at Mar 2025

PageGroup

Overview: PageGroup plc, along with its subsidiaries, offers recruitment consultancy and related services across the UK, Europe, the Middle East, Africa, Asia Pacific, and the Americas with a market cap of £1.05 billion.

Operations: PageGroup generates revenue through its recruitment consultancy and ancillary services across regions including the UK, Europe, the Middle East, Africa, Asia Pacific, and the Americas.

Estimated Discount To Fair Value: 14.3%

PageGroup, trading at £3.34, is undervalued compared to its fair value estimate of £3.9. Despite a decline in revenue and net income for 2024, earnings are forecast to grow significantly at 37.6% annually over the next three years, surpassing UK market averages. The company proposed a dividend increase but maintains an unstable dividend track record. Profit margins have decreased from 3.8% to 1.6%, yet return on equity is projected to be high at 35.1%.

Our comprehensive growth report raises the possibility that PageGroup is poised for substantial financial growth. Unlock comprehensive insights into our analysis of PageGroup stock in this financial health report.LSE:PAGE Discounted Cash Flow as at Mar 2025

Summing It All Up

Access the full spectrum of 57 Undervalued UK Stocks Based On Cash Flows by clicking on this link. Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments. Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.

Seeking Other Investments?

Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include LSE:CTEC LSE:GNS and LSE:PAGE.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments